In the latest trading session, 0.48 million Heron Therapeutics Inc (NASDAQ:HRTX) shares changed hands as the company’s beta touched 1.62. With the company’s most recent per share price at $1.57 changed hands at -$0.01 or -0.95% at last look, the market valuation stands at $245.81M. HRTX’s current price is a discount, trading about -150.32% off its 52-week high of $3.93. The share price had its 52-week low at $1.04, which suggests the last value was 33.76% up since then. When we look at Heron Therapeutics Inc’s average trading volume, we note the 10-day average is 2.67 million shares, with the 3-month average coming to 3.16 million.

Analysts gave the Heron Therapeutics Inc (HRTX) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.00. If we narrow down to specifics, the data shows that 0 out of 2 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended HRTX as a Hold, 2 felt it is a Buy and 0 rated the stock as Underweight. Heron Therapeutics Inc’s EPS for the current quarter is expected to be -0.03.

Heron Therapeutics Inc (NASDAQ:HRTX) trade information

Instantly HRTX was in red as seen in intraday trades today. With action -6.85%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -7.94%, with the 5-day performance at -6.85% in the red. However, in the 30-day time frame, Heron Therapeutics Inc (NASDAQ:HRTX) is 47.64% up. Looking at the short shares, we see there were 27.54 million shares sold at short interest cover period of 14.2 days.

The consensus price target for the stock as assigned by Wall Street analysts is 7, meaning bulls need an upside of 77.57% from its recent market value. According to analyst projections, HRTX’s forecast low is 5 with 9 as the target high. To hit the forecast high, the stock’s price needs a -473.25% plunge from its current level, while the stock would need to soar -218.47% for it to hit the projected low.

Heron Therapeutics Inc (HRTX) estimates and forecasts

Data shows that the Heron Therapeutics Inc share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -48.69% over the past 6 months, a 83.75% in annual growth rate that is considerably higher than the industry average of 16.40%. Year-over-year growth is forecast to reach 10.88% up from the last financial year.

Consensus estimates given by 3 financial analysts project the company’s revenue in the current quarter to hit an average of 37.37M. The company’s revenue for the corresponding quarters a year ago was 34.23M. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 9.15%.

Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 20.01%. The 2024 estimates are for Heron Therapeutics Inc earnings to increase by 83.89%, but the outlook for the next 5-year period is at 47.50% per year.

HRTX Dividends

Heron Therapeutics Inc is expected to release its next quarterly earnings report in January.

Heron Therapeutics Inc (NASDAQ:HRTX)’s Major holders

If we look at who the major shareholders are, we find that insiders hold 0.71% of Heron Therapeutics Inc shares while 81.53% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 82.12%. There are 81.53% institutions holding the Heron Therapeutics Inc stock share, with RUBRIC CAPITAL MANAGEMENT LP the top institutional holder. As of 2024-06-30, the company held 17.6678% of the shares, roughly 26.71 million HRTX shares worth $93.5 million.

VANGUARD GROUP INC holds the second largest percentage of outstanding shares, with 5.6984% or 8.62 million shares worth $30.16 million as of 2024-06-30.